MyoKardia Announces Danicamtiv Data Presentation at the European Society of Cardiology’s Virtual Heart Failure Association Discoveries
Late-Breaking Science Session 6 - Pharmacotherapy
Oral Presentation: Phase 2a Study of Danicamtiv (MYK-491) in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF)
HFA Discoveries will also publish data from nonclinical studies elucidating danicamtiv’s mechanism of activity in a presentation titled, “Danicamtiv (MYK-491) A Novel Small-Molecule Cardiac Activator: in vitro/in vivo Evidence for Overall Myocardial Inotropy,” by
Conference Call and Webcast
MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.
Michelle Corral Corporate Communications & Investor Relations MyoKardia, Inc. 650-351-4690 email@example.com
Source: MyoKardia, Inc.